AVROBIO Overview
- Founded
-
2015
- Status
-
Public
- Employees
-
91
- Stock Symbol
-
AVRO
- Share Price
-
$1.05
- (As of Monday Closing)
AVROBIO General Information
Description
Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.
Contact Information
- 100 Technology Square
- 6th Floor
- Cambridge, MA 02139
- United States
AVROBIO Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.05 | $1.11 | $0.56 - $1.93 | $47.2M | 44.1M | 2.13M | -$2.30 |
AVROBIO Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | (32,012) | (69,556) | (33,307) | 358,280 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (99,964) | (104,151) | (117,503) | (119,224) |
| Net Income | (101,014) | (105,890) | (119,126) | (119,712) |
| Total Assets | 83,005 | 103,949 | 203,837 | 271,234 |
| Total Debt | 18,335 | 16,463 | 14,945 | 0 |
AVROBIO Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AVROBIO Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
AVROBIO Comparisons
Industry
Financing
Details
000000
000000
AVROBIO Competitors (57)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biosceptre | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 000.00 | 00000000000 | 000.00 |
| 0000000 0000000000 | Formerly PE-Backed | Cambridge, MA | 000 | 00000 | 000000000 | 00000 |
| 000000000000 | Formerly VC-backed | Mountain View, CA | 000 | 00000 | 000000&0 | 00000 |
| 0000 000000 | Formerly VC-backed | Santa Monica, CA | 0000 | 00000 | 000000&0 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Houston, TX | 00 | 00000 | 00000000000 | 00000 |
AVROBIO Patents
AVROBIO Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4175717-A2 | Compositions and methods for treating neurocognitive disorders | Pending | 02-Jul-2020 | 0000000000 | |
| CA-3127804-A1 | Compositions and methods for treating neurocognitive disorders | Pending | 01-Feb-2019 | 0000000000 | |
| EP-3917623-A1 | Compositions and methods for treating neurocognitive disorders | Pending | 01-Feb-2019 | 0000000000 | |
| US-20220133850-A1 | Compositions and methods for treating neurocognitive disorders | Pending | 01-Feb-2019 | 0000000000 | |
| CA-3128003-A1 | Compositions and methods for treating neurocognitive disorders | Pending | 01-Feb-2019 | A61K38/18 |
AVROBIO Executive Team (21)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Erik Ostrowski | Chief Executive Officer & Chief Financial Officer, Finance | ||
| Geoff MacKay | Co-Founder, Chief Executive Officer, President & Board Member | ||
| Azadeh Golipour | Chief Technology Officer, Technology | ||
| Steven Avruch JD | Chief Legal Officer | ||
| Christopher Mason MD | Chief Scientific Officer & Founder |
AVROBIO Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Annalisa Jenkins MD | Self | Board Member | 000 0000 |
| Bruce Booth Ph.D | Atlas Venture | Chairman & Board Member | 000 0000 |
| Christopher Paige Ph.D | AVROBIO | Board Member | 000 0000 |
| Gail Farfel Ph.D | Self | Board Member | 000 0000 |
| Ian Clark | AVROBIO | Board Member | 000 0000 |
AVROBIO Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
AVROBIO Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
AVROBIO ESG
Risk Overview
Risk Rating
Updated December, 06, 2022
27 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,480
Rank
Percentile
Pharmaceuticals
Industry
00 of 905
Rank
Percentile
Biotechnology
Subindustry
00 of 404
Rank
Percentile
